Shares of cbdMD, Inc. (NYSE YCBD) rose 10.72% to $0.78 in Tuesday afternoon trading following the release of its fiscal first quarter 2026 results. The stock has traded in a 52-week range of $0.47 to $3.96, reflecting ongoing volatility in the cannabinoid sector as companies navigate shifting federal regulations and capital constraints.
The Charlotte-based CBD producer reported net sales of $5.02 million for the quarter ended Dec. 31, 2025, a 1.9% decrease from $5.11 million in the prior-year period. While revenue remained essentially flat, the company successfully narrowed its net loss attributable to common shareholders to $324,602, or $0.04 per share, compared to a significantly larger loss in the same quarter last year.
Gross profit margin contracted to 59.8% from 66.5% a year earlier, driven by higher cost of sales. The company reported a loss from operations of $286,288, while adjusted EBITDA was slightly negative at $35,914.
As of Dec. 31, 2025, cbdMD held $3.39 million in cash and cash equivalents, with working capital of approximately $5.4 million. Despite the improved liquidity position—bolstered by Series B and Series C preferred stock placements—management included a “going-concern” warning in its regulatory filing. The company stated there is substantial doubt about its ability to continue for the next 12 months without achieving sustainable profitability or securing additional financing.
Following the quarter’s end, cbdMD completed the acquisition of Bluebird Botanicals. The company expects the integration to contribute approximately $500,000 in additional quarterly revenue. Management also highlighted growth in its “Herbal Oasis” THC-infused beverage line, which recently expanded distribution into Louisiana.
However, the company faces a looming regulatory deadline. New federal limits set to take effect Nov. 12, 2026, would cap THC content in hemp-derived consumables nationwide. cbdMD warned that these restrictions, if implemented as written, would have a material adverse impact on its core product portfolio.
There were no analyst upgrades or price-target changes reported for YCBD today. The stock remains under pressure alongside the broader small-cap software and consumer health sectors, which have faced headwinds from high interest rates and cautious consumer spending.
For the full fiscal year 2025, cbdMD reported total net sales of $19.2 million, a 1.5% year-over-year decline. The company has focused on a third consecutive year of operating improvements, reducing its annual operating loss from $3.3 million to $2.1 million through disciplined marketing spend and supply chain optimization.
